RT @AurelieRheumo: Biosimilars cost less, but do they incur in indirect costs due to less dis control or more AE? DANBI
Tweet Content
Biosimilars cost less, but do they incur in indirect costs due to less dis control or more AE?
DANBIO study (>1,300 pts w/ IA)
Costs similar or decreased 9 mo after mandatory switching to ADA biosimilar (GP2017 or SB5)
Decrease 15% GP2017 switchers
#EULAR23 POS0376 @RheumNow https://t.co/bAeqYhNgf0
Show on Archive Page
On
Display in Search Results
On
PDQ
Off